Trump Unveils Tariff Roadmap For Generic Drugs; 0% For 2 Years, Then 100% And 200% Later

US President Donald Trump has announced a phased tariff plan for imported generic medicines. Duties stay at zero for the next two years. Then a 100% tariff is set for 2028. After that, it rises to 200%.

The proposal is part of the administration's push to encourage pharmaceutical companies to manufacture more medicines within the United States.

For India, which is the largest supplier of generic medicines to the US, the announcement could become an important development if the proposed timeline is implemented.

Tariff Schedule Announced

In a post on Truth Social, Trump said the new policy will come into effect from 1 August 2026.

Imported generic medicines will continue to enter the US without any tariff for two years. Beginning in August 2028, they will attract a 100% import duty for one year, after which the tariff will increase to 200%.

The administration has positioned the staggered rollout as a window for companies to establish manufacturing facilities inside the US before the higher duties begin.

Trump Explains The Objective

According to Trump, the proposal is intended to bring generic drug manufacturing back to the United States.

He said companies choosing not to build production capacity within the country during the transition period would eventually face significantly higher import costs.

Trump also noted that the existing policy covering patented, branded and innovative medicines will continue without any change.

Why India Is Watching The Announcement

Indian drugmakers have a sizeable presence in the American generic medicines market.

A Global Trade Research Initiative (GTRI) report revealed that India accounted for about $9.7 billion worth of pharmaceutical exports to the United States in FY25. India's overall pharmaceutical exports during this period stood at $25.8 billion.

By volume, Indian manufacturers account for around 40% of generic medicines sold in the United States, earning the country its reputation as one of the world's largest suppliers of affordable medicines.

Trade Agreement Adds Another Dimension

The practical impact of the proposed tariffs is still uncertain.

India and the US reached a trade understanding earlier this year under which India was expected to receive negotiated outcomes for generic pharmaceuticals and pharmaceutical ingredients.

Whether the latest US tariff proposal will affect that understanding, or whether certain products could receive exemptions, is likely to become clearer once the US releases detailed implementation guidelines.

Also Read - Cube Highways Trust Raises ₹1,687.5 Crore From Anchor Investors